Sangamo Therapeutics Stock Price, News & Analysis (NASDAQ:SGMO)

$16.35 -0.05 (-0.30 %)
(As of 12/17/2017 07:02 AM ET)
Previous Close$16.35
Today's Range$16.00 - $16.70
52-Week Range$2.85 - $18.40
Volume2.63 million shs
Average Volume1.47 million shs
Market Capitalization$1.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.15

About Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics logoSangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Receive SGMO News and Ratings via Email

Sign-up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGMO
CUSIP80067710
Phone510-970-6000

Debt

Debt-to-Equity Ratio0.02%
Current Ratio5.64%
Quick Ratio5.64%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$19.39 million
Price / Sales71.27
Cash FlowN/A
Price / CashN/A
Book Value$1.93 per share
Price / Book8.47

Profitability

Trailing EPS($0.69)
Net Income$-71,650,000.00
Net Margins-157.66%
Return on Equity-31.81%
Return on Assets-23.84%

Miscellaneous

Employees131
Outstanding Shares84,520,000

Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its quarterly earnings data on Thursday, November, 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.04. The biopharmaceutical company had revenue of $11.81 million for the quarter, compared to analyst estimates of $10.37 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The firm's revenue for the quarter was up 333.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.27) EPS. View Sangamo Therapeutics' Earnings History.

When will Sangamo Therapeutics make its next earnings announcement?

Sangamo Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Sangamo Therapeutics.

Where is Sangamo Therapeutics' stock going? Where will Sangamo Therapeutics' stock price be in 2017?

6 brokers have issued 1 year price objectives for Sangamo Therapeutics' stock. Their forecasts range from $6.00 to $30.00. On average, they expect Sangamo Therapeutics' share price to reach $18.60 in the next twelve months. View Analyst Ratings for Sangamo Therapeutics.

What are Wall Street analysts saying about Sangamo Therapeutics stock?

Here are some recent quotes from research analysts about Sangamo Therapeutics stock:

  • 1. According to Zacks Investment Research, "Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. " (11/15/2017)
  • 2. Cowen Inc analysts commented, "We hosted a group lunch meeting with SGMO management this week." (3/22/2017)
  • 3. Piper Jaffray Companies analysts commented, "Today Sangamo reported 4Q16 financial results, ending the quarter with ~$143M in cash. With updated 2017 guidance on operating expenses incorporated into our model, we expect this cash runway can fund the company through 1H18. This period should include the first safety and biomarker data from early cohorts of patients treated in its open, or soon-to-be opened, clinical trials for Hem A, Hem B, MPS I, and MPS II. Although we expect these early results in late'17/early '18 to focus primarily on safety and pharmacodynamic signals of activity and thus not yet be definitive for informing pivotal programs, we nonetheless believe this progress to be critical for evaluating turn-around efforts and establishing a new era of clinical achievement for Sangamo. That said, in advance of enrollment updates and increased visibility on clinical progress for Sangamo's broadening but early pipeline, we remain on the sidelines with a Neutral rating." (2/28/2017)

Who are some of Sangamo Therapeutics' key competitors?

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the folowing people:

  • Alexander D. Macrae Ph.D., President, Chief Executive Officer, Director (Age 54)
  • Kathy Y. Yi, Chief Financial Officer, Senior Vice President (Age 45)
  • Edward R. Conner M.D., Senior Vice President and Chief Medical Officer (Age 44)
  • Curt Herberts III, Senior Vice President and Chief Business Officer (Age 36)
  • Dale G. Ando M.D., Vice President - Therapeutic Development, Chief Medical Officer (Age 60)
  • Roger Jeffs Ph.D., Director
  • Joseph S. Zakrzewski, Director (Age 54)
  • Robert F. Carey, Independent Director (Age 58)
  • Stephen G. Dilly M.D. Ph.D., Independent Director (Age 57)
  • Steven J. Mento Ph.D., Independent Director (Age 65)

Who owns Sangamo Therapeutics stock?

Sangamo Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (6.21%), Point72 Asset Management L.P. (0.82%), Frontier Capital Management Co. LLC (0.58%), Royce & Associates LP (0.57%), Wells Fargo & Company MN (0.57%) and Granahan Investment Management Inc. MA (0.55%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Edward R Conner, Saira Ramasastry and William R Ringo. View Institutional Ownership Trends for Sangamo Therapeutics.

Who sold Sangamo Therapeutics stock? Who is selling Sangamo Therapeutics stock?

Sangamo Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Royce & Associates LP, Granahan Investment Management Inc. MA, Keybank National Association OH, Tocqueville Asset Management L.P., Gilder Gagnon Howe & Co. LLC, Iguana Healthcare Management LLC and Frontier Capital Management Co. LLC. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Curt A Herberts III, Edward R Conner, Saira Ramasastry and William R Ringo. View Insider Buying and Selling for Sangamo Therapeutics.

Who bought Sangamo Therapeutics stock? Who is buying Sangamo Therapeutics stock?

Sangamo Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., Point72 Asset Management L.P., Sanctuary Wealth Advisors LLC, Schwab Charles Investment Management Inc., EAM Investors LLC, Mckinley Capital Management LLC Delaware, Dynamic Technology Lab Private Ltd and OxFORD Asset Management LLP. View Insider Buying and Selling for Sangamo Therapeutics.

How do I buy Sangamo Therapeutics stock?

Shares of Sangamo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sangamo Therapeutics' stock price today?

One share of Sangamo Therapeutics stock can currently be purchased for approximately $16.35.

How big of a company is Sangamo Therapeutics?

Sangamo Therapeutics has a market capitalization of $1.38 billion and generates $19.39 million in revenue each year. The biopharmaceutical company earns $-71,650,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. Sangamo Therapeutics employs 131 workers across the globe.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]


MarketBeat Community Rating for Sangamo Therapeutics (SGMO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  203 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  369
MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sangamo Therapeutics (NASDAQ:SGMO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.672.502.57
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.83$16.20$13.60$9.40
Price Target Upside: 11.48% upside10.58% upside1.49% upside11.90% upside

Sangamo Therapeutics (NASDAQ:SGMO) Consensus Price Target History

Price Target History for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ:SGMO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/22/2017BarclaysInitiated CoverageOverweight$20.00N/AView Rating Details
11/15/2017WedbushReiterated RatingHold$6.00N/AView Rating Details
11/15/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$19.00N/AView Rating Details
10/13/2017Jefferies GroupReiterated RatingBuy$18.00N/AView Rating Details
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform$20.00 -> $30.00LowView Rating Details
3/22/2017CowenReiterated RatingBuyHighView Rating Details
8/4/2016Janney Montgomery ScottDowngradeBuy -> Neutral$15.00 -> $8.00N/AView Rating Details
2/10/2016J P Morgan Chase & CoReiterated RatingOverweight$16.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Sangamo Therapeutics (NASDAQ:SGMO) Earnings History and Estimates Chart

Earnings by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ SGMO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018($0.18)N/AView Earnings Details
11/9/2017Q3 2017($0.19)($0.15)$10.37 million$11.81 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.23)($0.17)$5.82 million$8.30 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.26)($0.23)$4.14 million$3.40 millionViewN/AView Earnings Details
2/28/2017Q416($0.26)($0.14)$3.91 million$8.90 millionViewListenView Earnings Details
10/26/2016Q316($0.25)($0.27)$4.24 million$2.82 millionViewListenView Earnings Details
8/3/2016Q216($0.24)($0.38)$5.38 million$3.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.24)($0.23)$5.49 million$3.94 millionViewN/AView Earnings Details
2/9/2016Q415($0.21)($0.20)$9.86 million$9.10 millionViewN/AView Earnings Details
10/28/2015Q315($0.25)($0.13)$13.09 million$8.57 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.17)$14.72 million$8.36 millionViewListenView Earnings Details
4/22/2015Q115($0.13)($0.08)$12.50 million$13.50 millionViewListenView Earnings Details
2/10/2015Q414($0.09)($0.06)$14.50 million$15.00 millionViewN/AView Earnings Details
10/22/2014Q314($0.04)($0.11)$8.27 million$12.40 millionViewListenView Earnings Details
7/23/2014Q214($0.14)($0.10)$7.84 million$10.38 millionViewListenView Earnings Details
5/6/2014Q114($0.13)($0.12)$6.59 million$8.10 millionViewListenView Earnings Details
2/11/2014Q413($0.10)($0.13)$8.90 million$6.90 millionViewListenView Earnings Details
10/23/2013Q313($0.11)($0.11)$5.52 million$5.70 millionViewN/AView Earnings Details
7/24/2013Q2 2013($0.12)($0.10)$4.77 million$6.90 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.17)($0.13)$3.79 million$4.60 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.12)($0.07)$5.95 million$8.93 millionViewN/AView Earnings Details
10/24/2012Q312($0.14)($0.11)$3.80 million$4.90 millionViewN/AView Earnings Details
7/25/2012($0.15)($0.11)ViewN/AView Earnings Details
5/2/2012($0.16)($0.14)ViewN/AView Earnings Details
10/25/2011($0.16)($0.18)ViewN/AView Earnings Details
7/27/2011($0.16)($0.20)ViewN/AView Earnings Details
4/26/2011($0.17)($0.21)ViewN/AView Earnings Details
2/2/2011($0.19)($0.18)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Sangamo Therapeutics (NASDAQ:SGMO) Earnings Estimates

2017 EPS Consensus Estimate: ($0.80)
2018 EPS Consensus Estimate: ($0.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.23)($0.24)
Q2 20172($0.23)($0.12)($0.18)
Q3 20172($0.22)($0.21)($0.22)
Q4 20172($0.23)($0.11)($0.17)
Q1 20181($0.25)($0.25)($0.25)
Q2 20181($0.25)($0.25)($0.25)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sangamo Therapeutics (NASDAQ:SGMO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Sangamo Therapeutics (NASDAQ SGMO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 64.35%
Insider Trades by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)
Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ SGMO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/6/2017Edward R ConnerVPSell5,000$16.24$81,200.00View SEC Filing  
12/4/2017Curt A Herberts IIIVPSell11,803$18.00$212,454.00View SEC Filing  
12/1/2017Curt A. Herberts IIIVPSell16,630$16.13$268,241.90View SEC Filing  
11/17/2017Saira RamasastryDirectorSell5,000$14.67$73,350.00View SEC Filing  
10/2/2017Curt A Herberts IIIVPSell15,000$15.25$228,750.00View SEC Filing  
9/20/2017William R RingoDirectorSell31,000$14.37$445,470.00View SEC Filing  
9/1/2017Curt A Herberts IIIVPSell15,000$15.00$225,000.00View SEC Filing  
8/14/2017Curt A Herberts IIIVPSell11,474$10.44$119,788.56View SEC Filing  
7/14/2017Curt A Herberts IIIVPSell15,000$10.00$150,000.00View SEC Filing  
6/1/2017Curt A. Herberts IIIVPSell2,000$6.80$13,600.00View SEC Filing  
5/12/2017Curt A. Herberts IIIVPSell2,639$8.02$21,164.78View SEC Filing  
8/1/2015Ra Capital Management, LlcMajor ShareholderSell27,770$12.82$356,011.40View SEC Filing  
7/30/2015Ra Capital Management, LlcMajor ShareholderSell109,590$12.42$1,361,107.80View SEC Filing  
7/29/2015Ra Capital Management, LlcMajor ShareholderSell1,407$12.41$17,460.87View SEC Filing  
7/28/2015Ra Capital Management, LlcMajor ShareholderSell60,081$12.11$727,580.91View SEC Filing  
7/25/2015Ra Capital Management, LlcMajor ShareholderSell47,429$12.31$583,850.99View SEC Filing  
7/24/2015Ra Capital Management, LlcMajor ShareholderSell124,050$12.28$1,523,334.00View SEC Filing  
7/17/2015Ra Capital Management, LlcMajor ShareholderBuy37,215$12.26$456,255.90View SEC Filing  
7/15/2015Edward O Lanphier IICEOSell25,000$10.43$260,750.00View SEC Filing  
7/13/2015Henry Ward WolffCFOSell12,000$10.00$120,000.00View SEC Filing  
7/1/2015Ra Capital Management, LlcMajor ShareholderSell82,700$16.01$1,324,027.00View SEC Filing  
6/16/2015Ra Capital Management, LlcMajor ShareholderSell250,500$16.55$4,145,775.00View SEC Filing  
6/9/2015Ra Capital Management, LlcMajor ShareholderSell83,500$15.50$1,294,250.00View SEC Filing  
6/6/2015Ra Capital Management, LlcMajor ShareholderSell135,101$14.29$1,930,593.29View SEC Filing  
6/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
6/5/2015Ra Capital Management, LlcMajor ShareholderSell115,102$14.13$1,626,391.26View SEC Filing  
6/4/2015Ra Capital Management, LlcMajor ShareholderSell70,640$13.10$925,384.00View SEC Filing  
6/3/2015Ra Capital Management, LlcMajor ShareholderSell76,833$12.86$988,072.38View SEC Filing  
6/3/2015William R RingoDirectorSell2,200$12.44$27,368.00View SEC Filing  
6/1/2015Philip D GregorySVPSell15,000$12.39$185,850.00View SEC Filing  
5/30/2015Ra Capital Management, LlcMajor ShareholderSell65,884$13.40$882,845.60View SEC Filing  
5/29/2015Ra Capital Management, LlcMajor ShareholderSell155,675$13.53$2,106,282.75View SEC Filing  
5/28/2015Ra Capital Management, LlcMajor ShareholderSell148,689$13.43$1,996,893.27View SEC Filing  
5/27/2015Ra Capital Management, LlcMajor ShareholderSell263,437$13.55$3,569,571.35View SEC Filing  
5/23/2015Ra Capital Management, LlcMajor ShareholderSell51,597$13.27$684,692.19View SEC Filing  
5/22/2015Ra Capital Management, LlcMajor ShareholderSell56,396$13.56$764,729.76View SEC Filing  
5/13/2015Ra Capital Management, LlcMajor ShareholderSell56,060$13.12$735,507.20View SEC Filing  
5/12/2015Ra Capital Management, LlcMajor ShareholderSell29,659$13.03$386,456.77View SEC Filing  
5/8/2015Ra Capital Management, LlcMajor ShareholderSell83,300$12.40$1,032,920.00View SEC Filing  
5/7/2015Ra Capital Management, LlcMajor ShareholderBuy35,736$12.09$432,048.24View SEC Filing  
5/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
5/4/2015William R RingoDirectorSell3,000$12.98$38,940.00View SEC Filing  
4/30/2015Ra Capital Management, LlcMajor ShareholderBuy124,500$13.45$1,674,525.00View SEC Filing  
4/28/2015Ra Capital Management, LlcMajor ShareholderBuy74,844$13.29$994,676.76View SEC Filing  
4/25/2015Ra Capital Management, LlcMajor ShareholderBuy166,000$13.63$2,262,580.00View SEC Filing  
4/22/2015Ra Capital Management, LlcMajor ShareholderSell352,750$14.86$5,241,865.00View SEC Filing  
4/17/2015Ra Capital Management, LlcMajor ShareholderBuy41,500$14.02$581,830.00View SEC Filing  
4/16/2015Ra Capital Management, LlcMajor ShareholderSell21,829$14.09$307,570.61View SEC Filing  
4/15/2015Edward O Lanphier IICEOSell25,000$15.33$383,250.00View SEC Filing  
4/15/2015Ra Capital Management, LlcMajor ShareholderBuy21,829$13.16$287,269.64View SEC Filing  
4/14/2015Ra Capital Management, LlcMajor ShareholderSell3,055$14.78$45,152.90View SEC Filing  
4/11/2015Ra Capital Management, LlcMajor ShareholderBuy116,992$14.48$1,694,044.16View SEC Filing  
4/10/2015Henry Ward WolffCFOSell12,000$15.31$183,720.00View SEC Filing  
4/10/2015Ra Capital Management, LlcMajor ShareholderBuy83,000$14.91$1,237,530.00View SEC Filing  
4/9/2015Ra Capital Management, LlcMajor ShareholderSell69,856$16.27$1,136,557.12View SEC Filing  
4/8/2015Ra Capital Management, LlcMajor ShareholderBuy121,876$15.49$1,887,859.24View SEC Filing  
4/7/2015Ra Capital Management, LlcMajor ShareholderBuy33,667$15.42$519,145.14View SEC Filing  
4/6/2015Dale G AndoCMOSell15,000$14.94$224,100.00View SEC Filing  
4/6/2015William R RingoDirectorSell2,200$14.95$32,890.00View SEC Filing  
4/4/2015Ra Capital Management, LlcMajor ShareholderBuy179,031$15.38$2,753,496.78View SEC Filing  
4/3/2015Ra Capital Management, LlcMajor ShareholderBuy195,126$16.61$3,241,042.86View SEC Filing  
4/1/2015Philip D GregorySVPSell15,000$15.15$227,250.00View SEC Filing  
4/1/2015Ra Capital Management, LlcMajor ShareholderSell250,000$18.01$4,502,500.00View SEC Filing  
3/28/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$17.10$1,436,400.00View SEC Filing  
3/27/2015Ra Capital Management, LlcMajor ShareholderBuy256,187$17.65$4,521,700.55View SEC Filing  
3/26/2015Ra Capital Management, LlcMajor ShareholderBuy210,013$18.14$3,809,635.82View SEC Filing  
3/25/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$19.42$1,631,280.00View SEC Filing  
3/21/2015Ra Capital Management, LlcMajor ShareholderBuy101,808$21.22$2,160,365.76View SEC Filing  
3/19/2015Henry Ward WolffCFOSell10,000$18.00$180,000.00View SEC Filing  
3/19/2015Ra Capital Management, LlcMajor ShareholderSell17,808$24.28$432,378.24View SEC Filing  
3/18/2015Ra Capital Management, LlcMajor ShareholderSell84,000$23.74$1,994,160.00View SEC Filing  
3/17/2015Ra Capital Management, LlcMajor ShareholderBuy52,161$23.02$1,200,746.22View SEC Filing  
3/16/2015Edward O Lanphier IICEOSell25,000$17.29$432,250.00View SEC Filing  
3/13/2015Ra Capital Management, LlcMajor ShareholderBuy71,319$22.76$1,623,220.44View SEC Filing  
3/12/2015Ra Capital Management, LlcMajor ShareholderSell123,480$23.40$2,889,432.00View SEC Filing  
3/10/2015Ra Capital Management, LlcMajor ShareholderBuy12,522$22.30$279,240.60View SEC Filing  
3/7/2015Ra Capital Management, LlcMajor ShareholderBuy258,377$22.25$5,748,888.25View SEC Filing  
3/6/2015Ra Capital Management, LlcMajor ShareholderSell61,483$24.10$1,481,740.30View SEC Filing  
3/3/2015Ra Capital Management, LlcMajor ShareholderSell84,000$18.21$1,529,640.00View SEC Filing  
3/3/2015William R RingoDirectorSell2,200$17.21$37,862.00View SEC Filing  
3/2/2015Philip D GregorySVPSell15,000$17.26$258,900.00View SEC Filing  
2/28/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.10$760,200.00View SEC Filing  
2/27/2015Ra Capital Management, LlcMajor ShareholderSell32,196$19.37$623,636.52View SEC Filing  
2/26/2015Ra Capital Management, LlcMajor ShareholderBuy74,194$19.57$1,451,976.58View SEC Filing  
2/20/2015Ra Capital Management, LlcMajor ShareholderSell35,319$18.40$649,869.60View SEC Filing  
2/19/2015Ra Capital Management, LlcMajor ShareholderSell6,720$18.51$124,387.20View SEC Filing  
2/18/2015Ra Capital Management, LlcMajor ShareholderSell11,172$18.11$202,324.92View SEC Filing  
2/14/2015Ra Capital Management, LlcMajor ShareholderSell15,380$18.61$286,221.80View SEC Filing  
2/13/2015Ra Capital Management, LlcMajor ShareholderSell15,409$18.46$284,450.14View SEC Filing  
2/12/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.04$757,680.00View SEC Filing  
2/12/2015Saira RamasastryDirectorSell10,000$15.00$150,000.00View SEC Filing  
2/11/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$19.65$825,300.00View SEC Filing  
2/7/2015Ra Capital Management, LlcMajor ShareholderSell34,688$18.52$642,421.76View SEC Filing  
2/6/2015Ra Capital Management, LlcMajor ShareholderSell7,312$18.42$134,687.04View SEC Filing  
2/5/2015Dale G AndoCMOSell15,000$12.93$193,950.00View SEC Filing  
2/5/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.23$765,660.00View SEC Filing  
2/3/2015William R RingoDirectorSell2,200$12.70$27,940.00View SEC Filing  
2/2/2015Philip D GregorySVPSell15,000$12.86$192,900.00View SEC Filing  
1/16/2015Edward O Lanphier IICEOSell25,000$14.22$355,500.00View SEC Filing  
1/12/2015Henry Ward WolffCFOSell12,000$15.87$190,440.00View SEC Filing  
1/5/2015Dale G AndoCMOSell15,000$15.19$227,850.00View SEC Filing  
1/5/2015William R RingoDirectorSell2,200$15.20$33,440.00View SEC Filing  
12/15/2014Edward O Lanphier IICEOSell25,000$15.40$385,000.00View SEC Filing  
12/15/2014John William LarsonDirectorSell10,000$16.28$162,800.00View SEC Filing  
12/9/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
12/1/2014Philip D GregorySVPSell15,000$11.68$175,200.00View SEC Filing  
11/17/2014Edward O Lanphier IICEOSell25,000$11.23$280,750.00View SEC Filing  
11/12/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
11/3/2014Philip D GregorySVPSell15,000$11.91$178,650.00View SEC Filing  
10/28/2014John William LarsonDirectorSell10,000$12.02$120,200.00View SEC Filing  
10/10/2014Henry Ward WolffCFOSell2,000$10.10$20,200.00View SEC Filing  
10/6/2014Dale G AndoCMOSell15,000$10.72$160,800.00View SEC Filing  
10/1/2014Philip D GregorySVPSell15,000$10.80$162,000.00View SEC Filing  
9/15/2014Edward O Lanphier IICEOSell25,000$12.14$303,500.00View SEC Filing  
9/10/2014Henry Ward WolffCFOSell2,000$12.31$24,620.00View SEC Filing  
9/5/2014Dale G AndoCMOSell15,000$12.20$183,000.00View SEC Filing  
9/4/2014John William LarsonDirectorSell10,000$12.81$128,100.00View SEC Filing  
8/15/2014Edward O Lanphier IICEOSell25,000$13.95$348,750.00View SEC Filing  
8/11/2014Henry Ward WolffCFOSell10,000$14.17$141,700.00View SEC Filing  
8/5/2014Dale G AndoCMOSell15,000$12.99$194,850.00View SEC Filing  
8/4/2014John William LarsonDirectorSell10,000$12.56$125,600.00View SEC Filing  
8/1/2014Philip D GregorySVPSell15,000$12.54$188,100.00View SEC Filing  
7/18/2014Edward O Lanphier IICEOSell25,000$12.16$304,000.00View SEC Filing  
7/10/2014Henry Ward WolffCFOSell15,000$13.26$198,900.00View SEC Filing  
7/1/2014Philip D GregorySVPSell15,000$15.66$234,900.00View SEC Filing  
6/23/2014Saira RamasastryDirectorSell5,550$15.53$86,191.50View SEC Filing  
6/16/2014Edward O Lanphier IICEOSell25,000$16.41$410,250.00View SEC Filing  
6/10/2014Henry Ward WolffCFOSell15,000$15.62$234,300.00View SEC Filing  
6/2/2014Philip D GregorySVPSell15,000$12.85$192,750.00View SEC Filing  
5/15/2014Edward Lanphier IICEOSell25,000$13.14$328,500.00View SEC Filing  
5/1/2014Philip GregorySVPSell15,000$13.68$205,200.00View SEC Filing  
4/28/2014Dale AndoCMOSell15,000$13.64$204,600.00View SEC Filing  
4/28/2014John William LarsonDirectorSell10,000$13.48$134,800.00View SEC Filing  
4/15/2014Edward Lanphier IICEOSell25,000$14.20$355,000.00View SEC Filing  
4/10/2014Henry Ward WolffCFOSell15,000$15.72$235,800.00View SEC Filing  
3/26/2014Dale AndoCMOSell15,000$18.65$279,750.00View SEC Filing  
3/21/2014Philip GregoryInsiderSell15,000$22.38$335,700.00View SEC Filing  
3/17/2014Edward Lanphier IICEOSell50,000$23.22$1,161,000.00View SEC Filing  
3/17/2014Saira RamasastryDirectorSell10,000$23.26$232,600.00View SEC Filing  
3/14/2014Steven MentoDirectorSell6,103$22.77$138,965.31View SEC Filing  
2/18/2014Edward Lanphier IICEOSell50,000$18.09$904,500.00View SEC Filing  
1/27/2014Dale AndoCMOSell15,000$18.58$278,700.00View SEC Filing  
1/10/2014Henry Ward WolffCFOSell10,000$18.69$186,900.00View SEC Filing  
1/2/2014Philip GregoryVPSell15,000$13.56$203,400.00View SEC Filing  
12/26/2013Dale AndoCMOSell15,000$14.37$215,550.00View SEC Filing  
11/15/2013Edward Lanphier IICEOSell25,000$10.11$252,750.00View SEC Filing  
11/5/2013Philip D GregoryVPSell15,000$9.60$144,000.00View SEC Filing  
10/28/2013Dale G AndoCMOSell15,000$10.39$155,850.00View SEC Filing  
10/21/2013Paul B ClevelandDirectorSell10,000$10.93$109,300.00View SEC Filing  
10/15/2013Edward O Lanphier IICEOSell25,000$11.32$283,000.00View SEC Filing  
10/10/2013Henry Ward WolffCFOSell10,000$11.28$112,800.00View SEC Filing  
10/1/2013Philip D GregoryVPSell15,000$10.54$158,100.00View SEC Filing  
9/16/2013Edward Lanphier IICEOSell25,000$11.29$282,250.00View SEC Filing  
9/10/2013Henry Ward WolffCFOSell10,000$10.86$108,600.00View SEC Filing  
9/3/2013Paul ClevelandDirectorSell7,278$10.30$74,963.40View SEC Filing  
9/3/2013Philip GregoryVPSell15,000$10.33$154,950.00View SEC Filing  
8/26/2013Dale AndoCMOSell15,000$10.04$150,600.00View SEC Filing  
8/15/2013Edward Lanphier IICEOSell25,000$10.12$253,000.00View SEC Filing  
8/13/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
8/1/2013Philip GregoryVPSell15,000$9.89$148,350.00View SEC Filing  
7/29/2013Philip D GregoryVPSell15,000$10.04$150,600.00View SEC Filing  
7/26/2013Dale G AndoCMOSell15,000$10.09$151,350.00View SEC Filing  
7/17/2013Edward O Lanphier IICEOSell25,000$10.00$250,000.00View SEC Filing  
7/17/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
7/15/2013Paul B ClevelandDirectorSell8,000$9.59$76,720.00View SEC Filing  
6/3/2013Philip D GregoryVPSell3,000$7.88$23,640.00View SEC Filing  
5/28/2013Dale G AndoCMOSell15,000$8.32$124,800.00View SEC Filing  
4/10/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
12/26/2012Dale G AndoCMOSell17,000$5.92$100,640.00View SEC Filing  
12/3/2012John William LarsonDirectorSell15,000$5.64$84,600.00View SEC Filing  
9/5/2012Dale G AndoCMOSell15,000$5.60$84,000.00View SEC Filing  
9/4/2012John William LarsonDirectorSell15,000$5.30$79,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sangamo Therapeutics (NASDAQ SGMO) News Headlines

Source:
DateHeadline
Why Sangamo Therapeutics (SGMO) Could Be Positioned for a SurgeWhy Sangamo Therapeutics (SGMO) Could Be Positioned for a Surge
finance.yahoo.com - December 14 at 10:53 AM
Head to Head Analysis: Sangamo Therapeutics (SGMO) and Its RivalsHead to Head Analysis: Sangamo Therapeutics (SGMO) and Its Rivals
www.americanbankingnews.com - December 12 at 1:40 PM
Sangamo Therapeutics, Inc. (SGMO) Given Average Rating of "Buy" by BrokeragesSangamo Therapeutics, Inc. (SGMO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 11 at 1:58 PM
 Analysts Anticipate Sangamo Therapeutics, Inc. (SGMO) Will Post Quarterly Sales of $11.28 Million Analysts Anticipate Sangamo Therapeutics, Inc. (SGMO) Will Post Quarterly Sales of $11.28 Million
www.americanbankingnews.com - December 10 at 1:02 PM
Sangamo Therapeutics, Inc. (SGMO) VP Sells $81,200.00 in StockSangamo Therapeutics, Inc. (SGMO) VP Sells $81,200.00 in Stock
www.americanbankingnews.com - December 8 at 8:52 PM
Sangamo Therapeutics (SGMO) Announces EMA Recommendation ... - StreetInsider.comSangamo Therapeutics (SGMO) Announces EMA Recommendation ... - StreetInsider.com
www.streetinsider.com - December 8 at 3:32 PM
Sangamo Therapeutics: Engineering Genomic Solutions For Rare ... - Seeking AlphaSangamo Therapeutics: Engineering Genomic Solutions For Rare ... - Seeking Alpha
seekingalpha.com - December 8 at 3:32 PM
Sangamo Announces European Medicines Agency Recommendation Of Orphan Medicinal Product Designation For Investigational Genome Editing Treatments For MPS I And MPS IISangamo Announces European Medicines Agency Recommendation Of Orphan Medicinal Product Designation For Investigational Genome Editing Treatments For MPS I And MPS II
finance.yahoo.com - December 8 at 10:56 AM
-$0.18 EPS Expected for Sangamo Therapeutics, Inc. (SGMO) This Quarter-$0.18 EPS Expected for Sangamo Therapeutics, Inc. (SGMO) This Quarter
www.americanbankingnews.com - December 8 at 3:24 AM
Sangamo Therapeutics, Inc. (SGMO) VP Curt A. Herberts III Sells 11,803 SharesSangamo Therapeutics, Inc. (SGMO) VP Curt A. Herberts III Sells 11,803 Shares
www.americanbankingnews.com - December 6 at 8:52 PM
ETFs with exposure to Sangamo Therapeutics, Inc. : December 5, 2017ETFs with exposure to Sangamo Therapeutics, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 3:32 PM
Sangamo Therapeutics, Inc. (SGMO) VP Curt A. Herberts III Sells 16,630 SharesSangamo Therapeutics, Inc. (SGMO) VP Curt A. Herberts III Sells 16,630 Shares
www.americanbankingnews.com - December 4 at 9:02 PM
Heres Why Sangamo Therapeutics Rose as Much as 14.9% Thursday - Motley FoolHere's Why Sangamo Therapeutics Rose as Much as 14.9% Thursday - Motley Fool
www.fool.com - December 2 at 10:55 AM
Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 3:46 PM
Who Are The Top Investors In Sangamo Therapeutics Inc (SGMO)?Who Are The Top Investors In Sangamo Therapeutics Inc (SGMO)?
finance.yahoo.com - November 24 at 6:40 PM
Sangamo Therapeutics, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Sangamo Therapeutics, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
www.prnewswire.com - November 24 at 2:01 PM
Sangamo Therapeutics, Inc. (SGMO) Earns Overweight Rating from Analysts at Barclays PLCSangamo Therapeutics, Inc. (SGMO) Earns Overweight Rating from Analysts at Barclays PLC
www.americanbankingnews.com - November 22 at 12:52 PM
Head to Head Survey: Sangamo Therapeutics (SGMO) versus The CompetitionHead to Head Survey: Sangamo Therapeutics (SGMO) versus The Competition
www.americanbankingnews.com - November 22 at 11:31 AM
 Brokerages Expect Sangamo Therapeutics, Inc. (SGMO) Will Announce Quarterly Sales of $11.28 Million Brokerages Expect Sangamo Therapeutics, Inc. (SGMO) Will Announce Quarterly Sales of $11.28 Million
www.americanbankingnews.com - November 22 at 8:44 AM
ETFs with exposure to Sangamo Therapeutics, Inc. : November 21, 2017ETFs with exposure to Sangamo Therapeutics, Inc. : November 21, 2017
finance.yahoo.com - November 22 at 7:54 AM
Sangamo Therapeutics (SGMO) & The Competition Head to Head ComparisonSangamo Therapeutics (SGMO) & The Competition Head to Head Comparison
www.americanbankingnews.com - November 22 at 3:18 AM
Sangamo Therapeutics, Inc. (SGMO) Director Sells $73,350.00 in StockSangamo Therapeutics, Inc. (SGMO) Director Sells $73,350.00 in Stock
www.americanbankingnews.com - November 21 at 9:08 PM
Wedbush Weighs in on Sangamo Therapeutics, Inc.s FY2017 Earnings (SGMO)Wedbush Weighs in on Sangamo Therapeutics, Inc.'s FY2017 Earnings (SGMO)
www.americanbankingnews.com - November 20 at 2:44 AM
Sangamo Therapeutics, Inc. (SGMO) Rating Increased to Overweight at Piper Jaffray CompaniesSangamo Therapeutics, Inc. (SGMO) Rating Increased to Overweight at Piper Jaffray Companies
www.americanbankingnews.com - November 19 at 10:58 PM
Sangamo Therapeutics, Inc. (SGMO) Upgraded to Buy by Zacks Investment ResearchSangamo Therapeutics, Inc. (SGMO) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - November 19 at 8:58 PM
Geron Corporation (GERN) and Sangamo Therapeutics (SGMO) Critical SurveyGeron Corporation (GERN) and Sangamo Therapeutics (SGMO) Critical Survey
www.americanbankingnews.com - November 19 at 3:24 AM
Sangamo Therapeutics (SGMO) Presents At Jefferies 2017 London Healthcare Conference - SlideshowSangamo Therapeutics (SGMO) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 18 at 11:52 AM
Here's Why Sangamo Therapeutics Rose as Much as 16.3% TodayHere's Why Sangamo Therapeutics Rose as Much as 16.3% Today
finance.yahoo.com - November 18 at 11:52 AM
Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SGMO-US : November 16, 2017Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SGMO-US : November 16, 2017
finance.yahoo.com - November 18 at 11:52 AM
Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% HigherSangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher
finance.yahoo.com - November 18 at 11:52 AM
Featured Company News - Sangamo Announced Treatment of First Patient in Phase-1/2 Clinical Trial Evaluating In Vivo Genome Editing Therapy for MPS IIFeatured Company News - Sangamo Announced Treatment of First Patient in Phase-1/2 Clinical Trial Evaluating In Vivo Genome Editing Therapy for MPS II
finance.yahoo.com - November 18 at 11:52 AM
Sangamo Therapeutics, Inc. – Value Analysis (NASDAQ:SGMO) : November 17, 2017Sangamo Therapeutics, Inc. – Value Analysis (NASDAQ:SGMO) : November 17, 2017
finance.yahoo.com - November 18 at 11:52 AM
Sangamo Therapeutics, Inc. (SGMO) Receives Consensus Rating of "Buy" from AnalystsSangamo Therapeutics, Inc. (SGMO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 16 at 12:16 PM
Wedbush Reiterates Hold Rating for Sangamo Therapeutics, Inc. (SGMO)Wedbush Reiterates Hold Rating for Sangamo Therapeutics, Inc. (SGMO)
www.americanbankingnews.com - November 15 at 11:36 PM
Sangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS IISangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II
finance.yahoo.com - November 15 at 8:24 AM
Sangamo Announces Strategic Investment In Manufacturing And Appointment Of Andy Ramelmeier As Head Of ... - PR Newswire (press release)Sangamo Announces Strategic Investment In Manufacturing And Appointment Of Andy Ramelmeier As Head Of ... - PR Newswire (press release)
www.prnewswire.com - November 11 at 6:34 PM
Sangamo Therapeutics, Inc. (SGMO) Releases Quarterly  Earnings Results, Beats Estimates By $0.04 EPSSangamo Therapeutics, Inc. (SGMO) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - November 10 at 9:08 PM
Why Sangamo Therapeutics Inc (SGMO) Could Be A BuyWhy Sangamo Therapeutics Inc (SGMO) Could Be A Buy
finance.yahoo.com - November 10 at 12:06 PM
Edited Transcript of SGMO earnings conference call or presentation 9-Nov-17 10:00pm GMTEdited Transcript of SGMO earnings conference call or presentation 9-Nov-17 10:00pm GMT
finance.yahoo.com - November 10 at 12:06 PM
Sangamo Announces Strategic Investment In Manufacturing And Appointment Of Andy Ramelmeier As Head Of Technical OperationsSangamo Announces Strategic Investment In Manufacturing And Appointment Of Andy Ramelmeier As Head Of Technical Operations
finance.yahoo.com - November 9 at 6:19 PM
Sangamo Therapeutics Reports Third Quarter 2017 Financial ResultsSangamo Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 6:19 PM
Sangamo Announces Plans For New Headquarters In Brisbane, CaliforniaSangamo Announces Plans For New Headquarters In Brisbane, California
finance.yahoo.com - November 9 at 6:19 PM
Sangamo reports 3Q lossSangamo reports 3Q loss
finance.yahoo.com - November 9 at 6:19 PM
Commit To Buy Sangamo Therapeutics At $8, Earn 21.9% Using OptionsCommit To Buy Sangamo Therapeutics At $8, Earn 21.9% Using Options
www.nasdaq.com - November 9 at 1:16 PM
Sangamo Therapeutics, Inc. to Host Earnings CallSangamo Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 1:16 PM
ETFs with exposure to Sangamo Therapeutics, Inc. : November 6, 2017ETFs with exposure to Sangamo Therapeutics, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 10:09 AM
Reviewing Acorda Therapeutics (ACOR) & Sangamo Therapeutics (SGMO)Reviewing Acorda Therapeutics (ACOR) & Sangamo Therapeutics (SGMO)
www.americanbankingnews.com - November 2 at 11:30 AM
Sangamo Therapeutics Announces Third Quarter 2017 Conference Call And WebcastSangamo Therapeutics Announces Third Quarter 2017 Conference Call And Webcast
finance.yahoo.com - November 1 at 8:39 AM
ETFs with exposure to Sangamo Therapeutics, Inc. : October 26, 2017ETFs with exposure to Sangamo Therapeutics, Inc. : October 26, 2017
finance.yahoo.com - October 27 at 5:45 PM
Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SGMO-US : October 23, 2017Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SGMO-US : October 23, 2017
finance.yahoo.com - October 24 at 9:56 AM

SEC Filings

Sangamo Therapeutics (NASDAQ:SGMO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sangamo Therapeutics (NASDAQ:SGMO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sangamo Therapeutics (NASDAQ SGMO) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.